SCHEMBL30009491

SCHEMBL30009491

O=S(=O)(Nc1ccc(-c2ccnc3[nH]ccc23)cc1)C1CCC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 1/20 0.67
IKBKB O14920 10/20 0.66
CHUK O15111 9/20 0.66
CIT O14578 6/20 0.53
ROCK1 Q13464 2/20 0.50
NEK1 Q96PY6 2/20 0.50
DAPK3 O43293 1/20 0.50
JAK2 O60674 1/20 0.50
PRKD3 O94806 1/20 0.50
MAP4K4 O95819 1/20 0.50
PAK4 O96013 1/20 0.50
CSF1R P07333 1/20 0.50
RET P07949 1/20 0.50
IGF1R P08069 1/20 0.50
FGFR1 P11362 1/20 0.50
PRKACA P17612 1/20 0.50
FLT1 P17948 1/20 0.50
LTK P29376 1/20 0.50
GRK5 P34947 1/20 0.50
KDR P35968 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30009888 0.96 PIK3C3 (0.69) PIK3C3IKBKBCHUKCITROCK1
SCHEMBL30008725 0.95 IKBKB (0.69) PIK3C3IKBKBCHUKCITROCK1
SCHEMBL30009389 0.83 JAK1 (0.65) PIK3C3IKBKBCHUKCITJAK1
SCHEMBL30009401 0.82 PIK3C3 (0.57) PIK3C3IKBKBCHUKROCK1NEK1
SCHEMBL30009495 0.82 JAK1 (0.62) PIK3C3IKBKBCHUKCITJAK1
SCHEMBL30009578 0.81 PIK3C3 (0.55) PIK3C3IKBKBCHUKCITNEK1
SCHEMBL30008716 0.80 IKBKB (0.65) PIK3C3IKBKBCHUKCITROCK1
SCHEMBL24805260 0.80 IKBKB (0.76) PIK3C3IKBKBCHUKCITROCK1
SCHEMBL30009478 0.80 IKBKB (0.61) PIK3C3IKBKBCHUKCITROCK1
SCHEMBL30009885 0.79 IKBKB (0.71) PIK3C3IKBKBCHUKCITROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 PIK3C3 288/4885IKBKB 294/4885CHUK 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.